AU2521799A - Supporting material for medicinal purposes - Google Patents
Supporting material for medicinal purposes Download PDFInfo
- Publication number
- AU2521799A AU2521799A AU25217/99A AU2521799A AU2521799A AU 2521799 A AU2521799 A AU 2521799A AU 25217/99 A AU25217/99 A AU 25217/99A AU 2521799 A AU2521799 A AU 2521799A AU 2521799 A AU2521799 A AU 2521799A
- Authority
- AU
- Australia
- Prior art keywords
- backing material
- adhesive composition
- medical purposes
- purposes according
- backing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 151
- 239000000853 adhesive Substances 0.000 claims abstract description 103
- 230000001070 adhesive effect Effects 0.000 claims abstract description 73
- 239000000203 mixture Substances 0.000 claims description 126
- 239000013543 active substance Substances 0.000 claims description 33
- 239000004831 Hot glue Substances 0.000 claims description 24
- 238000000576 coating method Methods 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 13
- 230000002787 reinforcement Effects 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 239000006260 foam Substances 0.000 claims description 10
- 230000009477 glass transition Effects 0.000 claims description 10
- 239000004745 nonwoven fabric Substances 0.000 claims description 8
- 238000007639 printing Methods 0.000 claims description 7
- 238000007650 screen-printing Methods 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 2
- 239000007769 metal material Substances 0.000 claims description 2
- 239000005871 repellent Substances 0.000 claims description 2
- 238000009958 sewing Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- -1 polyethylene Polymers 0.000 description 18
- 230000035882 stress Effects 0.000 description 18
- 239000003570 air Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 10
- 230000035699 permeability Effects 0.000 description 10
- 229920001400 block copolymer Polymers 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000011505 plaster Substances 0.000 description 9
- 229920000728 polyester Polymers 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000004952 Polyamide Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229920002647 polyamide Polymers 0.000 description 8
- 229920000297 Rayon Polymers 0.000 description 7
- 239000012943 hotmelt Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000007596 consolidation process Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000009736 wetting Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 238000003490 calendering Methods 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 229920001169 thermoplastic Polymers 0.000 description 4
- 239000004416 thermosoftening plastic Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940127554 medical product Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- QQRSPHJOOXUALR-UHFFFAOYSA-N Apiole Chemical compound COC1=CC(CC=C)=C(OC)C2=C1OCO2 QQRSPHJOOXUALR-UHFFFAOYSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- 239000004760 aramid Substances 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 229920003235 aromatic polyamide Polymers 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 238000001266 bandaging Methods 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- 229960002881 clemastine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229920000359 diblock copolymer Polymers 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- WFLSCFISQHLEED-UHFFFAOYSA-N isoaminile Chemical compound CN(C)C(C)CC(C(C)C)(C#N)C1=CC=CC=C1 WFLSCFISQHLEED-UHFFFAOYSA-N 0.000 description 2
- 229960004216 isoaminile Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- OJCPSBCUMRIPFL-UHFFFAOYSA-N prolintane Chemical compound C1CCCN1C(CCC)CC1=CC=CC=C1 OJCPSBCUMRIPFL-UHFFFAOYSA-N 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 229920006132 styrene block copolymer Polymers 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 description 1
- CEMAWMOMDPGJMB-CYBMUJFWSA-N (2r)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- ZWLMLVIUWRUDBD-BTJKTKAUSA-N (z)-but-2-enedioate;3-(2-methoxy-10h-phenothiazin-10-ium-10-yl)propyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2N(CCCN(C)C)C3=CC(OC)=CC=C3SC2=C1 ZWLMLVIUWRUDBD-BTJKTKAUSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- KVHHQGIIZCJATJ-UHFFFAOYSA-N 1-(4-chlorophenyl)-4-(dimethylamino)-2,3-dimethyl-2-butanol Chemical compound CN(C)CC(C)C(C)(O)CC1=CC=C(Cl)C=C1 KVHHQGIIZCJATJ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- IKQUUYYDRTYXAP-UHFFFAOYSA-N 3-methylpenta-1,4-diene Chemical compound C=CC(C)C=C IKQUUYYDRTYXAP-UHFFFAOYSA-N 0.000 description 1
- PFEOZHBOMNWTJB-UHFFFAOYSA-N 3-methylpentane Chemical compound CCC(C)CC PFEOZHBOMNWTJB-UHFFFAOYSA-N 0.000 description 1
- QKICWELGRMTQCR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)azaniumyl]pentyl-diethylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 QKICWELGRMTQCR-UHFFFAOYSA-N 0.000 description 1
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- WNCAVNGLACHSRZ-KAMYIIQDSA-N Allithiamine Chemical compound C=CCSSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-KAMYIIQDSA-N 0.000 description 1
- WNCAVNGLACHSRZ-UHFFFAOYSA-N Allithiamine Natural products C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229930008564 C01BA04 - Sparteine Natural products 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- SIDLZWOQUZRBRU-UHFFFAOYSA-N Methyprylon Chemical compound CCC1(CC)C(=O)NCC(C)C1=O SIDLZWOQUZRBRU-UHFFFAOYSA-N 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SIVHMKRQTQHNIO-UHFFFAOYSA-N [3-(dimethylamino)-2-hydroxypropyl] 4-(propylamino)benzoate Chemical compound CCCNC1=CC=C(C(=O)OCC(O)CN(C)C)C=C1 SIVHMKRQTQHNIO-UHFFFAOYSA-N 0.000 description 1
- BGYHLZZASRKEJE-UHFFFAOYSA-N [3-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxy]-2,2-bis[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxymethyl]propyl] 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CCC(=O)OCC(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 BGYHLZZASRKEJE-UHFFFAOYSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 229960003216 aceclidine Drugs 0.000 description 1
- WRJPSSPFHGNBMG-UHFFFAOYSA-N acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001171 adenosinetriphosphoric effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- NFHVTCJKAHYEQN-UHFFFAOYSA-N amfetaminil Chemical compound C=1C=CC=CC=1C(C#N)NC(C)CC1=CC=CC=C1 NFHVTCJKAHYEQN-UHFFFAOYSA-N 0.000 description 1
- 229950000762 amfetaminil Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 229940070436 apiole Drugs 0.000 description 1
- 235000002484 apiole Nutrition 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- 229960001498 benactyzine Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- DLNKOYKMWOXYQA-IONNQARKSA-N cathine Chemical compound C[C@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-IONNQARKSA-N 0.000 description 1
- 229960003609 cathine Drugs 0.000 description 1
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940031956 chlorothymol Drugs 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002735 clobutinol Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N cyclopentamine Chemical compound CNC(C)CC1CCCC1 HFXKQSZZZPGLKQ-UHFFFAOYSA-N 0.000 description 1
- 229960003263 cyclopentamine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 1
- 229950010160 dimethocaine Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- MSYUMPGNGDNTIQ-UHFFFAOYSA-N dixyrazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC(C)CN1CCN(CCOCCO)CC1 MSYUMPGNGDNTIQ-UHFFFAOYSA-N 0.000 description 1
- 229960005146 dixyrazine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- SLWGJZPKHAXZQL-UHFFFAOYSA-N emylcamate Chemical compound CCC(C)(CC)OC(N)=O SLWGJZPKHAXZQL-UHFFFAOYSA-N 0.000 description 1
- 229960000650 emylcamate Drugs 0.000 description 1
- AXJXURWWUFZZKN-UHFFFAOYSA-N enallylpropymal Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)N(C)C1=O AXJXURWWUFZZKN-UHFFFAOYSA-N 0.000 description 1
- 229950009181 enallylpropymal Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UVTJKLLUVOTSOB-UHFFFAOYSA-N etaqualone Chemical compound CCC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C UVTJKLLUVOTSOB-UHFFFAOYSA-N 0.000 description 1
- 229950010472 etaqualone Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 229950010338 fencarbamide Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 229960005220 fluanisone Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000007646 gravure printing Methods 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960003861 mephenesin Drugs 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229950008620 methopromazine Drugs 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- QXLPXWSKPNOQLE-UHFFFAOYSA-N methylpentynol Chemical compound CCC(C)(O)C#C QXLPXWSKPNOQLE-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960000316 methyprylon Drugs 0.000 description 1
- 229960005103 metixene Drugs 0.000 description 1
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000012764 mineral filler Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 229960003226 nikethamide Drugs 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 229960004036 nonivamide Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012766 organic filler Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229960004227 phensuximide Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- FWWDFDMCZLOXQI-UHFFFAOYSA-N pivhydrazine Chemical compound CC(C)(C)C(=O)NNCC1=CC=CC=C1 FWWDFDMCZLOXQI-UHFFFAOYSA-N 0.000 description 1
- 229950008099 pivhydrazine Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002742 polystyrene-block-poly(ethylene/propylene) -block-polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960005253 procyclidine Drugs 0.000 description 1
- 229960002262 profenamine Drugs 0.000 description 1
- CDOZDBSBBXSXLB-UHFFFAOYSA-N profenamine Chemical compound C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 CDOZDBSBBXSXLB-UHFFFAOYSA-N 0.000 description 1
- 229960004654 prolintane Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- BZGIPVGCJGXQTA-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] n,n-diphenylcarbamothioate Chemical compound C=1C=CC=CC=1N(C(=O)SCCN(CC)CC)C1=CC=CC=C1 BZGIPVGCJGXQTA-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 229960001945 sparteine Drugs 0.000 description 1
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 1
- 239000005315 stained glass Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229960002415 trichloroethylene Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- PRBORDFJHHAISJ-UHFFFAOYSA-N tybamate Chemical compound CCCCNC(=O)OCC(C)(CCC)COC(N)=O PRBORDFJHHAISJ-UHFFFAOYSA-N 0.000 description 1
- 229960002560 tybamate Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0223—Adhesive bandages or dressings with fluid retention members characterized by parametric properties of the fluid retention layer, e.g. absorbency, wicking capacity, liquid distribution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0226—Adhesive bandages or dressings with fluid retention members characterised by the support layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/025—Adhesive bandages or dressings characterised by the skin-adhering layer having a special distribution arrangement of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0256—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the parametric properties of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
The invention relates to supporting material for medicinal purposes. The supporting material is characterized in that it is a non-woven material which is topstitched with sewing threads and which has a maximum tensile strength of at least 10 N/cm. In addition, the supporting material is partially or completely coated on at least one side with a doped adhesive material.
Description
WO 99/39756 PCT/EP99/00738 Description Backing material for medical purposes 5 The invention relates to a backing material for medical purposes, preferably a medical plaster, which is coated on at least one side completely or partially with a doped adhesive composition. 10 As backing materials for medical purposes, numerous materials based on films, wovens, knits, nonwovens, gels or foams have already been disclosed and are also employed in practice. The materials, which are often coated with a self-adhesive composition as well, are 15 required to be skin-compatible, generally permeable to air and water vapour, and also easy to model and conformable. Based on these requirements, a very thin or soft backing is frequently preferred. For handling and in use, however, the backing materials are also 20 required to be of sufficient strength and possibly of limited extensibility. Furthermore, the backing material should retain sufficient strength and low extensibility even after becoming wet through. 25 Thin backings, especially those made of nonwovens, are highly permeable to air and water vapour. For certain applications, however, their strength is too low and their elongation too high. Moreover, the cushioning effect is inadequate for these favourable backings. 30 Specific applications, an example being rheumatism plasters, require inelastic backings having high strength in the direction of stress. This is achieved by using woven or knitted fabric backings, usually of cotton or viscose. Backing materials of this kind, with i.-j appropriately high basis weight, are generally cost ~U, M5 -2 intensive. High conformability and modelability can only be achieved by means of woven fabric of relatively low strength. When such fabrics are stressed, however, they generally exhibit too low a degree of cushioning, 5 which is undesirable for the application. When the dressings listed become wet through, they generally lose strength or become more extensible. This is likewise undesirable for their use and has to date 10 been compensated by more frequent changing of dressings, which, however, is cost-intensive. Thus, AU 73555/74 describes by way of example a glass filament-reinforced backing material for medical 15 application based on foam. US 4,668,563 describes a glass fibre-reinforced material which, however, is elastic. All backing materials mentioned, however, are not reinforced by 20 stitching. DE 44 42 092 and DE U 94 01 037 describe adhesive tapes based on stitchbonded webs which are partially coated on the reverse side of the backing. Such adhesive tapes 25 are used preferably in cable bandaging. DE 44 42 093 is also based on the use of a nonwoven as backing for an adhesive tape; in this case, a cross laid fibre web is described which is reinforced by the formation of loops from the fibres of the web. 30 DE 44 42 507 likewise discloses an adhesive tape for cable bandaging, but bases it on so-called Kunit or Multikunit webs. A utility or special suitability of these backing materials for medical purposes, however, cannot be 35 inferred from the documents--cited. In particular, the publications give indications neither of sufficient U) L1 -3 skin compatibility of the adhesive compositions nor of functionally secured bonding on the skin or an advantageous permeability to air and water vapour. Furthermore, doping with active substances is not 5 mentioned. US 4,773,238 describes a fibre web with lengthwise overstitching, the stitching seams being intended to amount to no more than 20% by weight based on the 10 weight of the total nonwoven. Proposed in accordance with the invention is the utility as an insert for filters in dust filtration. US 4,967,740 gives a general disclosure of backing 15 materials for use in medical supply, which are produced in a one-step process. In this process, the backing is impregnated simultaneously with an elastomer and with a release solution. In this way, the material can be presented without release paper on a roll. Doping with 20 active substances is not mentioned. In a listing of a large number of appropriate backings, mention is made, inter alia, of overstitched nonwovens, without the skilled worker being given any indication 25 as to how the nonwoven should, specifically, be configured in order to meet the requirements placed on a medical backing. Transdermal therapeutic systems (TTS) are forms of 30 administration of medicaments which deliver one or more medicaments to the skin over a defined period at their site of use. A distinction is made between systemic and local administration forms. With systemic administration forms, the active ,N 5 substance passes through -the skin into the blood circulation by diffusion and is able to act within the
U)L
-4 body as a whole. Local administration forms, on the other hand, act only at the applied sites. The active substance remains in the skin or in the underlying layers. 5 Strongly adhering plasters are usually coated over the whole of their area with a rubber adhesive composition. These adhesive compositions then permit secure bonding, for example at critical points such as joints, over the 10 duration of several days. The adhesive bonding of such products to the skin, however, shows distinct skin irritations following removal, and mechanical stressing of the skin. Without auxiliary means, the bond cannot be released painlessly. 15 Further adhesive compositions are based on acrylate systems or on block copolymers. The abovementioned adhesive compositions may be 20 pressure-sensitive self-adhesive compositions, in which case the compositions may be present for processing in a carrier matrix. The carrier matrix is understood to comprise common organic or inorganic solvents or dispersants. 25 Systems without a carrier matrix are referred to as 100% systems and are likewise not unknown. They are processed in the elastic or thermoplastic state. A common mode of processing is that of the melt. 30 Pressure-sensitive hot-melt adhesive compositions of this kind have also already been described in the prior art. They are based on natural or synthetic rubbers and/or other synthetic polymers. 35 An advantage of the 100% sys-t-ems is that they avoid the operation of removing the carrier matrix, i.e. the -5 auxiliary means, thereby raising the productivity of processing and at the same time reducing the expenditure on machinery and the energy costs. In addition, this reduces the occurrence of residues of 5 the carrier matrix. This, in turn, is to the benefit of a reduction in the allergenic potential. Because of their high level of hardness, adhesion to the skin is a problem for such 100% systems. 10 It is also known to apply such self-adhesive compositions not only over the entire area but also in the form of a pattern of dots, for example by screen printing (DE-C 42 37 252), in which case the dots of 15 adhesive may also differ in their size and/or distribution (EP-B 353 972), or by gravure printing of lines which interconnect in the longitudinal and transverse directions (DE-C 43 08 649). 20 The advantage of the patterned application is that the adhesive materials, given an appropriate porous backing material, are permeable to air and water vapour and, in general, are readily redetachable. 25 A disadvantage of these products, however, is that if the area covered by the adhesive layer, which per se is impermeable, is too large there is a corresponding reduction in the permeability to air and water vapour, and the consumption of adhesive composition rises; and 30 also, if the area covered by the adhesive layer is small, the adhesion properties deteriorate, i.e. the product is detached too readily from the substrate, especially in the case of heavy, textile backing materials. - Numerous embodiments of active substance plasters have -6 already been described in the prior art, some of which operate in accordance with the reservoir principle, where the active substance is delivered, for example, via a membrane, in some cases also with a matrix system 5 or with a relatively complex multilayer structure. It is also known that the adhesive composition of the plaster may be employed as the active substance matrix. In addition to self-adhesive compositions applied from 10 solution, hot-melt adhesive compositions have also been proposed for this purpose, as . for example in EP-A 663 431, EP-A 452 034, EP-A 305 757, DE-A 43 10 012, DE-A 42 22 334 and DE-C 42 24 325. The active substances listed in these documents, if named 15 at all, have been systemic ones. Use of the backing of the invention is not described. As examples of active substance plasters, mention may be made of the active substance plasters which aid the 20 circulation, belonging to the group of the locally active therapeutic systems. The use of such plasters is indicated for the treatment of rheumatic complaints, sciatica, lumbago, stiff neck, shoulder/arm pain and also muscular strains and sprains, muscular aching or 25 muscle, joint and nerve pain in the region of the locomotor system. Capsaicin, belladonna and nonivamide are known active substances in such locally acting, circulation-aiding 30 plasters. Because of their use on the locomotor system they are generally required to adhere strongly. Usually, the plasters are coated over their whole area with a resin-rubber adhesive composition which comprises the active substance. 35 However, plasters of this kind, which usually have to 0" -7 be applied over a relatively large area, may in some cases lead to mechanical skin irritations following removal in the case of sensitive patients. 5 The disadvantage depicted also applies to active substance plasters comprising substances other than those mentioned. For instance, WO 94/02123 describes an active substance 10 plaster based on pressure-sensitive hot-melt adhesive compositions and comprising low-melting and/or readily volatile active substances in a concentration of from 2.5 to 25% by weight. Use of the backing of the invention is not described. 15 EP 0 663 431 A2, EP 0 443 759 A3, EP 0 452 034 A2 and US 5,371,128 describe uses of pressure-sensitive, silicone-based hot-melt adhesives with various additives and in differentiated structural forms. Use 20 of the backing of the invention is not described. DE 43 10 012 Al describes the structure of a dermal therapeutic system comprising meltable poly(meth)acrylate mixtures. 25 In particular, the release of a plurality of active substances from polymer systems which [lacuna] only one polymer type appears difficult. Systems comprising two or more polymer types are, however, critical in their compatibility. Use of the backing of the invention is 30 not described. DE 43 16 751 Cl describes a multi-chamber system for administering active substances. EP 0 439 180 describes an active substance plaster for 5 administering tulobuterol. EP 0 305 757 describes an active substance plaster for -8 administering nicotine. EP 0 305 758 describes an active substance plaster for administering nitroglycerine. EP 0 305 756 describes an adhesive composition of 5 substances and its preparation and use. Use of the backing of the invention is not described. DE 37 43 945 describes an adhesive composition for delivering substances, and the production process. In 10 the case of the pressure-sensitive hot-melt adhesive composition described, which is based on SIS, the device is not self-adhesive. The processing ranges indicated therein lie well below those of hot-melt adhesive compositions and for such described systems 15 would not provide sufficient anchoring of the adhesive composition. Use of the backing of the invention is not described. WO 96/22083 indicates a polyisobutylene adhesive for 20 transdermal purposes, which has a tackifier with a high glass transition point. Use of the backing of the invention is not described. JP 07-196505 describes the administration of 25 inkomethacin [sic] in hot-melt pressure-sensitive adhesives. In this case, a polyethylene foam is used as backing material. Use of the backing of the invention is not described. 30 The object of the invention was to provide a nonwoven based backing material which has been coated with a doped adhesive composition and is suitable for medical requirements and which, moreover, does not have the disadvantages known from the prior art. 35 This object is achieved by a nonwoven as set down in -9 the main claim. An alternative embodiment is the subject-matter of the subsidiary Claim 2. The under sayings [sic] embrace advantageous variants of the subject-matter of the invention. 5 Accordingly, a nonwoven overstitched by means of yarns is used as backing material for medical purposes, 'the number of stitches on the nonwoven being advantageously at least 3/cm, preferably from 5/cm to 50/cm. The 10 ultimate tensile stress strength of the backing material is at least 10 N/cm, preferably from 20 to 450 N/cm, with particular preference from 30 to 250 N/cm, and the backing material is coated partially or over its full area on at least one side with a doped 15 adhesive composition. The yarns preferably have a water absorption of less than 30%, with particular preference less than 20%. The water absorption can be regenerated by the atmospheric 20 humidity. Accordingly, materials which can be used for the yarns are, advantageously, polymeric fibres made from polypropylene, polyester, polyamide, aramid or 25 polyethylene, and also mineral fibres such as glass fibres or carbon fibres. In addition it is also possible to use multistrand yarns or mixed multistrands, especially Sirospun yarns. For specific applications, single- or multi-strand fibre blend yarns 30 may also be employed. Furthermore, the yarns can have been at least partly coloured in order to make the backing material more visually appealing. For specific applications, the yarn can also be 35 elastic. From this there is---t-hen regenerated an elastic base support having an elongation of up to 250% at a - 10 load of 10 N/cm. Mention may be made here, for example, as a polyamide yarn (Lycra , DuPont) [sic]. A backing material of this kind generates a compression force of from 0.2 N/cm to 10 N/cm at an elongation of 5 from 20% to 70% and is used in compression technology. In the case of the alternative embodiment of the subject-matter of the invention, a nonwoven is used as backing material for medical purposes. In this case, 10 the nonwoven is reinforced by the formation of stitches formed by loops from the fibres of the web, the number of stitches on the web being advantageously at least 3/cm, preferably from 5/cm to 50/cm. The ultimate tensile stress strength of the backing material is at 15 least 10 N/cm, preferably from 20 to 450 N/cm, with particular preference from 50 to 250 N/cm, and the backing material is coated partially or over its full area on at least one side with a doped adhesive composition. 20 The backing materials are based on known nonwovens which are mechanically consolidated either by overstitching with separate yarns or by looping. In the first case, the resulting structures are the 25 web-yarn stitchbonds. For their production, a fibre web is taken, which can, for example, be in cross-plating configuration, and is overstitched with separate yarns in pillarstitch formation or tricot formation. These nonwovens are known by the name "Maliwatt" (from 30 the company Malimo) or Arachne. With the second type of consolidation, again, preferably a cross-plated web is taken. In the course of the consolidation operation, needles draw out fibres from the web itself and form them into loops, with 5 stitches being formed in pillarstitch formation. This web stitchbond is in circulation under the name - 11 "Malivlies" [Mali Fleece], again from the company Malimo. An overview of the various kinds of mechanically consolidated fibre nonwovens can be found in the 5 article "Kaschierung von Autopolsterstoffen mit Faservliesen" [Laminating car upholstery materials with fibre webs] by G. Schmidt, Melliand Textilberichte 6/1992, pages 479 to 486. 10 Advantageously, the webs have longitudinal stitches, in which case the orientation of the yarns ought to be aligned in accordance with the stresses on the backing material in use. 15 Starting materials which can be used for the nonwoven material are generally all organic and inorganic, natural- and synthetic-based fibre materials. Examples that may be mentioned include viscose, cotton, silk, polypropylene, polyester, polyurethane, polyamide, 20 aramid or polyethylene, and also mineral fibres such as glass fibres or carbon fibres. The present invention is, however, not restricted to the said materials; rather, it is possible to use a large number of other fibres for web formation. 25 The fibres used to form the web preferably have a water retention capacity of more than 0.5%, preferably between 2 to [sic] 70%, with particular preference between 3 and 50%. 30 In one preferred embodiment, the backing material has an ultimate tensile stress elongation of less than 40%, preferably less than 15%, with particular preference less than 10%. For a web overstitched with yarns, this is achieved 35 firstly by the use of a ya-r-n- material having a higher modulus of elasticity and secondly with the use of - 12 stitching which ensures a yarn position which is stretched as much as possible. Advantageous combinations of material are, for example, 5 yarns of high-strength polymer fibres such as polyamide, polyester, highly stretched polyethylene, or mineral fibres such as glass, and initial web materials such as cotton or staple viscose rayon. 10 For a web in which the formation of stitches takes place by the loops being formed from the fibres of the web, the material of the initial web should be selected accordingly; corresponding comments apply to the stitching. 15 It has also been found advantageous for the backing material to have a basis weight of up to 500 g/m 2 , preferably from 10 to 350 g/m 2 20 In one further advantageous embodiment, the backing material can be torn by hand perpendicular to the orientation of the stitches and/or in the direction of the stitches. This finds its application when the backing material of the invention is wound up on itself 25 to form a roll. In another embodiment, this tearability is unnecessary. In this case, the materials involved may be prepunched plaster materials. 30 Furthermore, the backing material may have been reinforced with one or more monofil, multifil, staple fibre or spun fibre yarns and/or with oriented high strength fibres, the yarns and/or fibres having in 35 particular a strength of at---east 40 cN/tex. In addition it is also possible to employ multi-strand - 13 yarns or mixed multistrands, especially Sirospun yarns. For specific applications, single- or multi-strand fibre blend yarns may also be employed. These may comprise, for example, core-spun yarns or special 5 staple fibre core-spun yarns. An advantage here is that by combining different fibre types it is possible to achieve particular properties or specific properties in the reinforcement thread. Examples of this are the combinations of polyester or 10 polyamide with cotton or staple viscose rayon. The reinforcement fibres or filaments here can consist of organic or inorganic materials: for example, and preferably, glass, carbon, polyester or specific 15 polyamides, and the reinforcement fibres may also have been at least partly coloured in order to render the backing material more visually appealing. In this way it is readily possible to differentiate visually the reinforced backing. Coloured glass or polymer filaments 20 are particularly suitable for this purpose. In one advantageous embodiment the backing material attains through the addition of high-strength fibres or filaments an ultimate tensile stress strength of more 25 than 40 cN/tex, an ultimate tensile stress strength of more than 50 N/cm and an ultimate tensile stress elongation of less than 25% with a basis weight of less than 140 g/m 2 30 The number of attached or introduced filaments or high strength fibres depends primarily on the particular intended use and on the desired ultimate tensile stress strength and ultimate tensile stress elongation of the backing material, on its inherent nature and on the 35 respective strength of the fibres and filaments themselves, and can therefore be varied within - 14 relatively wide limits. Advantageous combinations of material are, for example, reinforcement filaments or fibres of high-strength 5 polymer fibres such as polyamide, polyester, highly stretched polyethylene, or mineral fibres such as glass, and initial web materials such as cotton or staple viscose rayon. 10 In addition, the reinforcements are preferably inserted specifically in accordance with the direction of stress of the backing material, i.e. in the longitudinal direction. If more appropriate, however, they can also extend only or additionally in the transverse or 15 oblique direction or, for example, in curved, spiral or zigzag formation, or randomly. In one further advantageous embodiment, the backing material can be torn by hand perpendicular to the 20 orientation of the reinforcement and/or in the direction of the reinforcement. With greater strength of the nonwoven material and an increasing proportion of reinforcement fibres, the 25 backing withstands greater stress and loading. Even very highly reinforced backing materials are able to absorb or allow the passage of large amounts of moisture, and hence provide a pleasant sensation for the user, with the reinforcements absorbing little or 30 no moisture and so undergoing no change in their properties. The adhesive composition may preferably include different active substances, the quantitative 35 concentrations of the active-substance or substances in the adhesive composition further preferably being - 15 between 0.01 to about 60% by weight, preferably from 0.1 to 20% by weight. Under the designation "active substances" in connection 5 with the present invention there are understood chemical elements, organic and inorganic compounds which are able to migrate from the constituents of a generic adhesive composition that comprise them and so bring about a desired effect. Among the fields of 10 application of the adhesive composition of the invention, human and veterinary medicine is of particular importance, a configuration of the invention in plaster form being particularly preferred here. Typical substances which may be administered in this 15 case by way of devices produced in accordance with the invention are the following: aceclidine, amfetaminil, amfetamine, amyl nitrite, apophedrine, atabrine, alpostadil, azulene, arecoline, 20 anethole, amylene hydrate, acetylcholine, acridine, adenosine triphosphoric acid, L-malic acid, alimemazine, allithiamine, allyl isothiocyanate, aminoethanol, apyzine, apiole, azatadine, alprenolol, ethinazone, benzoyl peroxide, benzyl alcohol, 25 bisabolol, bisnorephedrine, butacetoluide, benactyzine, camphor, colecalciferol, chloral hydrate, clemastine, chlorobutanol, capsaicin, cyclopentamine, clobutinol, chamazulene, dimethocaine, codeine, chloropromazine, quinine, chlorothymol, cyclophosphamide, cinchocaine, 30 chlorambuzil, chlorphenesin, diethylethane, divinyl ethane, dexchlorpheniramine, dinoprostone, dixyrazine, ephedrine, ethosuximide, enallylpropymal, emylcamate, erythrol tetranitrate, emetine, enflurane, eucalyptol, etofenamate, ethylmorphine, fentanyl, fluanisone, 35 guaiazulene, halothane, hyoscyamine, histamine, fen carbamide, hydroxycaine, hexylresorcinol, isoaminile
-A
1 - 16 citrate, isosorbide dinitrate, ibuprofen, iodine, iodoform, isoaminile, lidocaine, lopirine, levamisole, methadone, methyprylon, methylphenidate, mephenesin, methylephedrine, meclastine, methopromazine, 5 mesuximide, nikethamide, norpseudoephedrine, menthol, methoxyfluran, methylpentinol, metixene, mesoprostol, oxytetracaine, oxyprenolol, oxyphenbutazone, oxyquinoline, pinene, prolintane, procyclidine, piperazine, pivazide, phensuximide, procaine, 10 phenindamine, promethazine, pentetrazol, profenamine, perazine, phenol, pethidine, pilocarpine, prenylamine, phenoxybenzamine, resochin, scopolamine, salicylic acid ester, sparteine, trichloroethylene, timolol, trifluoperazine, tetracaine, trimipramine, 15 tranylcypromine, trimethadione, tybamate, thymol, thioridazine, valproic acid and verapamil, and also other active substances familiar to the skilled worker that can be absorbed through the skin, including mucosae. This list is of course not exhaustive. 20 The active substances are dispersed in the adhesive composition preferably in commercial homogenizers, such as for example mixers, kneading apparatus, roll mills or screw systems. The active substance can be added to 25 the ready-prepared adhesive composition. The active substance can also, for example, be incorporated into an intermediate stage or into the initial mixture. As adhesive compositions it is possible with advantage 30 to use self-adhesive compositions based on natural and synthetic rubbers and on other synthetic polymers such as acrylates, methacrylates, polyurethanes, polyolefins, polyvinyl derivatives, polyesters or silicones with corresponding additives such as tackifier resins, plasticiz-e-rs, stabilizers and other /'SA&,auxiliaries where necessary.
- 17 The adhesive composition may additionally comprise polymers which form a physically or chemically crosslinked gel. 5 Thermoplastic hot-melt adhesive compositions, in particular, have advantageous properties and are favoured for reasons concerned with the production process. 10 Their softening point should be higher than 500C, since the application temperature in the case of the coating is generally at least 900C, preferably between 1200C and 1500C, or between 180 0 C and 2200C in the case of 15 special adhesive compositions such as silicones. If desired, postcrosslinking by means of high-energy radiation such as UV rays or electron beams may be applied. 20 Preferred hot-melted adhesive compositions based on block copolymers are notable for their diverse possibilities for variation, since the controlled reduction in the glass transition temperature of the self-adhesive composition as a result of the selection 25 of the tackifiers, plasticizers, polymer molecule size and molecular distribution of the starting components ensures the required bonding to the skin in a manner appropriate to their function, even at critical points of the human locomotor system. 30 The high shear strength of the hot-melt adhesive composition is achieved through the high cohesiveness of the polymer. The good tack results from the range of tackifiers and plasticizers employed. 35 For especially strongly adhesive systems, the hot-melt - 18 adhesive composition is preferably based on block copolymers, especially A-B-, A-B-A block copolymers or mixtures thereof. The hard phase A is principally polystyrene or its derivatives and the soft phase B 5 contains ethylene, propylene, butylene, butadiene, isoprene or mixtures thereof, particular preference being given here to ethylene and butylene or mixtures thereof. 10 Polystyrene blocks, however, may also be present in the soft phase B in amounts of up to 20%. The overall proportion of styrene should, however, always be less than 35% by weight. Preferably, styrene proportions of between 5% and 30% are preferred, since a relatively 15 low proportion of styrene makes the adhesive composition more conformable. The controlled blending of diblock and triblock copolymers is particularly advantageous, preference 20 being given to a proportion of diblock copolymers of less than 80% by weight. In one advantageous embodiment the hot-melt adhesive composition has the following stated composition: 25 from 10% by weight to 90% by weight of block copolymers, - from 5% by weight to 80% by weight of tackifiers such as oils, waxes, resins and/or mixtures thereof, preferably mixtures of resins and oils, 30 less than 60% by weight of plasticizers, - less than 15% by weight of additives, - less than 5% by weight of stabilizers, and - less than 60% by weight of active substance. 35 The aliphatic or aromatic -oils, waxes and resins used as tackifiers are preferably hydrocarbon oils, waxes - 19 and resins, the consistency of the oils, such as paraffinic hydrocarbon oils, or of the waxes, such as paraffinic hydrocarbon waxes, accounting for their favourable effect on bonding to the skin. Plasticizers 5 used are medium-chain or long-chain fatty acids and/or their esters. These additions serve to establish the adhesion properties and the stability. If desired, further stabilizers and other auxiliaries are employed. 10 Filling the adhesive composition with mineral or organic fillers, fibres or hollow or solid microbeads is possible. The self-adhesive composition has a softening point of 15 more than 700C, preferably from 800C to 140 0 C. The hot-melt self-adhesive compositions are preferably formulated so that at a frequency of 0.1 rad/s they have a dynamic-complex glass transition temperature of 20 less than 15*C, preferably from 30C to -300C, with very particular preference from -30C to -250C. Stringent requirements are placed in terms of the adhesion properties on medical backing materials. For 25 ideal use the hot-melt adhesive composition should possess a high tack. There should be functionally appropriate bond strength to the skin and to the reverse of the backing. So that there is no slipping, the hot-melt adhesive composition is also required to 30 have a high shear strength. By the controlled reduction in the glass transition temperature of the adhesive composition, which is a result of the selection of the tackifiers, the plasticizers, the polymer molecule size and the 35 molecular distribution of t-he starting components, the required, functionally appropriate bonding to the skin - 20 and to the reverse of the backing is achieved. The high shear strength of the adhesive composition which is employed here is obtained by virtue of the high cohesiveness of the block copolymer. The good tack 5 is the result of the range of tackifiers and plasticizers employed. Product properties such as tack, glass transition temperature and shear stability can be quantified 10 readily using a dynamo-mechanical frequency measurement. In this case, use is made of a rheometer controlled by shearing stress. The results of this measurement method give information of the physical properties of a substance by taking 15 into account the viscoelastic component. In this instance, at a predetermined temperature, the self adhesive composition is set in oscillation between two plane-parallel plates at variable frequencies and with low deformation (linear viscoelastic region) . Via a 20 pickup control unit, with computer assistance, the quotient (Q = tan S) between the loss modulus (G'', viscous component) and the storage modulus (G', elastic component) is determined. 25 Q = tan 8 = G''/G' A high frequency is chosen for the subjective sensing of the tack, and a low frequency for the shear strength. 30 The glass transition temperature is the temperature at which amorphous or partially crystalline polymers undergo transition from the liquid or rubber-elastic state to the hard-elastic or glassy state, or vice 35 versa (R6mpp Chemie-Lexikon, 9th Ed., Volume 2, page - 21 1587, Georg Thieme Verlag Stuttgart - New York, 1990) It corresponds to the maximum of the temperature function at a predetermined frequency. For medical applications in particular, a relatively 5 low glass transition point is required. Designation Tg Conformability Tack low low frequency/ RT high frequency/ frequency RT Hot-melt adhesive -10 i 2 0 C tan 8 = 0.35 ± 0.05 tan 5 = 1.70 ± 0.10 composition A Hot-melt adhesive -9 2 0 C tan 8 = 0.22 ± 0.03 tan 8 = 1.00 ±0.03 composition B Preference is given in accordance with the invention to self-adhesive compositions for which the ratio of the 10 viscous component to the elastic component at a frequency of 100 rad/s and at 25 0 C is greater than 0.7, or to self-adhesive compositions for which the ratio of the viscous component to the elastic component at a frequency of 0.1 rad/s at 250C is less than 0.4, 15 preferably from 0.35 to 0.02 and, with very particular preference, between 0.3 and 0.1. It is also advantageous, especially with use for medical products, if the adhesive composition is 20 applied partially to the backing material, for example by means of halftone printing, screen printing, thermoflex printing or intaglio printing, because backing materials which have been adhesively treated in a continuous applied line may, under unfavourable 25 circumstances, on application, induce mechanical irritations of the skin and are generally impermeable to air and water vapour. Preference is given to application in the form of 0 polygeometric domes and, especially, domes where the
:,
- 22 ratio of diameter to height is less than 5:1. Printed application of other forms and patterns on the backing material is also possible - for example, a printed image in the form of alphanumeric character 5 combinations or patterns such as matrices, stripes and zigzag lines. The adhesive composition can be distributed uniformly over the backing material; alternatively, it can be applied with a thickness or density which varies over 10 the area, as is appropriate for the function of the product. The principle of thermal screen printing consists in the use of a rotating, heated, seamless, drum-shaped, 15 perforated, cylindrical screen which is fed via a nozzle with the preferred hot-melt self-adhesive composition. A specially shaped nozzle lip (circular or square bar) presses the hot-melt adhesive composition, which is fed in via a channel, through the perforation 20 of the screen wall and onto the backing web that is conveyed past it. This web is guided by means of a counterpressure roller against the external jacket of the heated screen drum at a rate which corresponds to the peripheral speed of the rotating screen drum. 25 In this context, the formation of the small domes of adhesive takes place by the following mechanism: The pressure of the nozzle bar conveys the hot-melt 30 adhesive composition through the screen perforation onto the backing material. The size of the domes formed is determined by the diameter of the screen perforation. The screen is lifted from the backing in accordance with the rate of transportation of the 6 35 backing web (rotary speed -- o-f the screen drum) . As a consequence of the high adhesion of the adhesive - 23 composition and the internal cohesion of the hot-melt, the limited supply of hot-melt adhesive composition in the perforations is drawn in sharp definition from the base of the dome that is already adhering to the 5 backing and is conveyed by the pressure of the bar onto the backing. After the end of this transportation, the more or less strongly curved surface of the dome forms over the pre defined base area in dependence on the rheology of the 10 hot-melt adhesive composition. The height-to-base ratio of the dome depends on the ratio of the performation diameter to the wall thickness of the screen drum and on the physical properties (flow behaviour, surface tension and contact angle on the backing material) of 15 the self-adhesive composition. For the screen in thermal screen printing, the web-to hole ratio can be less than 3:1, preferably less than or equal to 1:1, and in particular equal to 1:3. 20 The above-described mechanism of formation of the domes preferentially requires backing materials that are absorbent or at least wettable by hot-melt adhesive compositions. Non-wetting backing surfaces must be 25 pretreated by chemical or physical techniques. This can be effected by additional measures such as corona discharge, for example, or by coating with substances which improve wetting. 30 Using the printing technique indicated it is possible to lay down the size and shape of the domes in a defined manner. The bond strength values which are relevant for use and which determine the quality of the products formed are within very narrow tolerances in 35 the case of proper coating-.--The base diameter of the domes can be chosen from 10 to 5000 pm, the height of - 24 the domes from 20 to about 2000 pm, preferably from 50 to 1000 pm, the low-diameter range being intended for smooth backings and the range of greater diameter and greater dome height being intended for rough or highly 5 porous backing materials. The positioning of the domes on the backing is laid down in a defined manner by the geometry of the applicator unit, for example the gravure or screen geometry, which can be varied within wide limits. With 10 the aid of the parameters indicated it is possible, by way of adjustable variables, to establish with very great precision the desired profile of properties of the coating, harmonized with various backing materials and applications. 15 The backing material is preferably coated at a rate of more than 2 m/min, preferably from 20 to 200 m/min, the chosen coating temperature being greater than the softening temperature. 20 The self-adhesive composition can be applied to the backing material at a weight per unit area of greater than 15 g/m 2 , preferably between 90 g/m 2 and 500 g/m 2 , with very particular preference between 130 g/m 2 and 25 500 g/m 2 . The percentage of the area that is coated with the self-adhesive composition should be at least 20% and can range up to approximately 95%, for specific 30 products preferably from 40% to 60% and from 70% to 95%. This can be achieved, if appropriate, by multiple application, in which case it is also possible, if desired, to use self-adhesive compositions having different properties. 35 The combination of the preferred hot-melt adhesive - 25 composition and the preferred partial coating on the one hand ensures reliable bonding of the medical product to the skin and, on the other hand, allergic or mechanical skin irritations, at least which are 5 visually perceptible, are ruled out, even in the case of use extending over a number of days. The epilation of corresponding body regions and the transfer of composition to the skin are negligible owing to the high cohesiveness of the adhesive, since 10 the adhesive does not attach to the skin and hair; rather, the anchorage of the adhesive composition to the backing material, at up to 12 N/cm (sample width), is good for medical applications. 15 Because of the intended breakage points that have been formed in the coating, layers of skin are no longer displaced with one another or against one another in the course of detachment. The non-displacement of these layers of skin and the relatively low level of 20 epilation lead to an unprecedented degree of painlessness in such strongly adhering systems. In addition, the individual biomechanical control of bond strength, which exhibits a demonstrable reduction in the bond strength of these plasters, assists 25 detachability. The applied backing material shows good proprioreceptive effects. Depending on the backing material and its temperature sensitivity, the hot-melt adhesive composition can be 30 applied directly or can be applied first to an auxiliary support and then to the ultimate backing. In addition, subsequent calendering of the coated product and/or pretreatment of the backing, such as corona irradiation, may be advantageous for better anchorage 35 of the adhesive film.
- 26 In addition, treatment of the hot-melt adhesive composition with an electron beam postcrosslinking, or a UV irradiation, may result in an improvement in the desired properties. 5 In a further advantageous embodiment, the self-adhesive compositions are foamed before being applied to the backing material. 10 In this case the self-adhesive compositions are preferably foamed using inert gases such as nitrogen, carbon dioxide, noble gases, hydrocarbons or air, or mixtures thereof. In many cases, foaming additionally by thermal decomposition of gas-evolving substances, 15 such as azo, carbonate and hydrazide compounds, has been found to be suitable. The degree of foaming, i.e. the gas content, should be at least about 5% by volume and can range up to about 20 85% by volume. In practice, levels of from 10% by volume to 75% by volume, preferably 50% by volume, have been found to be appropriate. Operating at relatively high temperatures of approximately 100 0 C and with a comparatively high internal pressure produces very 25 open-pored adhesive foam layers which are particularly permeable to air and water vapour. The advantageous properties of the foamed self-adhesive coatings, such as low consumption of adhesive, high tack and good conformity, even on uneven surfaces, 30 owing to the elasticity and plasticity, and also the initial tack, can be utilized to best effect, very particularly, in the field of medical products. The use of breathable coatings in conjunction with 35 elastic and likewise breathable backing materials produces a level of wear comfort which is perceived 27 subjectively by the user as being more pleasant. A particularly suitable method of preparing the foamed self-adhesive composition operates by the foam mixing 5 system. In this system, the thermoplastic self-adhesive composition is reactive with the intended gases such as, for example, nitrogen, air or carbon dioxide in various volume proportions (from about 10% by volume to 80% by volume) in a stator/rotor system under high 10 pressure and at a temperature above the softening point (approximately 120 0 C). Whereas the gas entry pressure is greater than 100 bar, the mixing pressures between gas and thermoplastic in the system are from 40 to 100 bar, preferably from 40 15 to 70 bar. The pressure-sensitive adhesive foam produced in this way can subsequently be passed through a line into the applicator unit. In the applicator unit, commercially customary nozzles, extruder systems or chamber systems are used. 20 By virtue of the foaming of the self-adhesive composition and the open pores in the composition which form as a result, and given the use of an inherently porous backing, the products coated with the adhesive 25 composition have good permeability to water vapour and air. The amount of adhesive compositions required is considerably reduced without adverse effect on the adhesion properties. The adhesive compositions have a surprisingly good tack, since per gramme of composition 30 there is more volume and thus more adhesion surface for wetting of the substrate that is to be bonded, and the plasticity of the adhesive compositions is increased by virtue of the foam structure. Anchoring to the backing material is also improved by this means. Moreover, the 35 foamed adhesive coating, as-- already mentioned, gives the products a soft and conforming feel.
W%~
- 28 Foaming also generally reduces the viscosity of the adhesive compositions. This lowers the melt energy, and even thermally unstable backing materials can be coated 5 directly. The backing material coated with the adhesive composition can have an air permeability of greater than 1 cm 3 / (cm 2 *s) , preferably greater than 10 15 cm 3 / (cm 2 *s) , with very particular preference greater than 70 cm 3 /(cm 2 *s), and also a water vapour permeability of greater than 500 g/ (m 2 *24h) , preferably greater than 1000 g/(m 2 *24h), with very particular preference greater than 2000 g/ (m 2 *24h). 15 Furthermore, the backing material can also be provided with other finishes or treatments. These include, for example, corona, flame or plasma pretreatments, in order to increase the anchoring of the self-adhesive 20 composition to the base web. In addition, the calendering of the backing material or of the web as yet untreated with pressure-sensitive self-adhesive composition, for the purpose of further consolidation and/or improvement in the anchoring of the pressure 25 sensitive self-adhesive composition, is an advantageous treatment. In addition, on the side opposite to that coated with self-adhesive composition, the backing material can be 30 finished with a water-repellent layer or impregnation which prevents rapid soaking on contact with water or perspiration. In addition to the known impregnations, this can also be done by the sewing-on of a sheet, advantageously a water vapour permeable sheet, by means 35 of yarns directly during the---consolidation of the web. The backing material can, furthermore, be finished with - 29 a release layer or impregnation and/or coating which reduces the bond strength of the self-adhesive composition. In this case as well, in addition to the known release materials, it is also possible to sew on 5 a sheet, advantageously a water vapour permeable sheet, directly during the consolidation of the web. Another procedure which has been found to be advantageous is the lamination of the web backing with 10 at least one additional layer of foams or sheets, since by this means a combination of properties of particular type is obtained. A foam has a substantially higher damping quality than an unlaminated backing. Sheets can be used, for example, for sealing the surface. 15 Furthermore, the backing material can be coated with metallic substances by vapour deposition. Finally, following the coating operation, the backing 20 material can be lined with a backing material which repels adhesive, such as siliconized paper, or can be provided with a wound pad or with padding. It is particularly advantageous for the backing 25 material to be sterilizable, preferably by means of y (gamma) radiation. Particularly suitable for subsequent sterilization, therefore, are hot-melt adhesive compositions based on block copolymers which contain no double bonds. This applies in particular to 30 styrene-butylene-ethylene-styrene block copolymers or styrene-butylene-styrene block copolymers. This procedure is not accompanied by any application significant changes in the adhesive properties. 35 The backing material of -- the invention has a bond strength on the reverse side of the backing of at least - 30 0.5 N/cm, in particular a bond strength of between 2.5 N/cm and 5 N/cm. Greater bond strengths may be achieved on other substrates. 5 Advantageously it has been found that a reinforced backing material with such an adhesive coating, on becoming wet through - as is unavoidable, for example, in the course of water sports activities - has a stability which is better than that of customary 10 commercial backing material. The relative increase in the ultimate tensile stress elongation of self adhesively treated backing materials according to the invention after becoming wet through is only half as great as in the case of customary commercial self 15 adhesively treated backing materials. By virtue of this the backing materials of the invention, which indeed are thus essentially inelastic, become useful for specific medical purposes, and it is 20 also possible to employ backing materials whose use hitherto was impossible owing to lack of strength and/or excessive elongation. With preference it is possible to use backing materials 25 based on wovens, knits, nonwovens or composite products, provided they otherwise meet the requirements of medical use. Example 1 30 The text below describes by way of example a preferred backing material, without thereby wishing to restrict the invention unnecessarily. 35 The backing material used w-as- a viscose-based nonwoven. The nonwoven was overstitched with a polyester yarn, - 31 the yarn count being 22/cm sample width. The water absorption of the polyester yarn was 0.3%. The backing material was calendered and impregnated. The backing material thus produced had an ultimate 5 tensile stress strength of 50 N/cm and an ultimate tensile stress elongation of 28% in the lengthwise direction. The basis weight was 120 g/cm 2 . Wetting the backing material completely was not possible owing to the choice of reinforcement materials. Without a load, 10 the backing material has a thickness of 1.0 mm, which brings about a good cushioning effect. The backing material had an air permeability of 100 cm 3 /(cm 2 *s) and a water vapour permeability of greater than 2500 g/(m 2 *24h) and could be torn both 15 partly and right through by hand in both crosswise and lengthwise directions. The hot-melt adhesive composition was applied to the backing by thermal screen printing. 20 The hot-melt adhesive composition was composed as follows: - an A-B/A-B-A block copolymer, which consists of hard and soft segments, with a ratio of A-B-A to 25 A-B of 2:1 and a styrene content in the polymer of 13 mol-%; its proportion in the adhesive composition is 40% by weight (Kraton G), - a paraffinic hydrocarbon wax with a proportion in the adhesive composition of 51% by weight, 30 - hydrocarbon resins with a proportion of 7.5% by weight (Super Resin HC 140), - an ageing inhibitor with a proportion of less than 0.5% by weight (Irganox). - a hyperaemic active substance (nonanonyl 35 vanillylamide); fraction--of 1%.
- 32 The components employed were homogenized in a thermal mixer at 125 0 C. The glass transition by the abovementioned method was -9*C. 5 Direct coating took place at 50 m/min and at a temperature of 120"C. The backing material was partially coated with 120 g/m 2 using a 14 mesh screen with a thickness of 300 pm. 10 The bandage produced by this method exhibited reversible detachment from the skin and good permeability for air and water vapour. No skin irritations were observed, and the epilation observed following the removal of the bandage was negligible. 15 Example 2 The backing material used was a viscose-based nonwoven. The nonwoven was overstitched with a polyamide yarn, 20 the yarn count being 7/cm sample width. The backing material was calendered and impregnated. The backing material thus produced had an ultimate tensile stress strength of 12 N/cm and an ultimate 25 tensile stress elongation of 28% in the lengthwise direction. The basis weight was 140 g/cm 2 . Wetting the backing material completely was not possible owing to the choice of reinforcement materials. Without a load, the backing material has a thickness of 1.2 mm, which 30 brings about a good cushioning effect. The backing material had an air permeability of 80 cm 3 /(cm 2 *s) and a water vapour permeability of greater than 2500 g/(m 2 *24h) and could be torn both partly and right through by hand in both crosswise and 35 lengthwise directions.
- 33 This hot-melt pressure-sensitive adhesive composition was composed as follows: - an SEPS block copolymer, which consists of hard 5 and soft segments, with a styrene content in the polymer of 13 mol-%; its proportion in the adhesive composition is 15% by weight (Kuraray Co.) - a paraffinic hydrocarbon wax with a proportion in 10 the adhesive composition of 44% by weight - an ageing inhibitor with a proportion of less than 1.0% by weight (Irganox 1010 Ciba) - salicylic acid with a proportion of 40% 15 The components of the adhesive that were employed were homogenized in a thermal mixer at 185 0 C 3.5. The active substance was added in the cooling phase at 120 0 C and homogenization was continued in the mixer for 130 minutes. 20 The softening point of this adhesive composition was approximately 85 0 C (DIN 52011) and the adhesive composition showed a viscosity of 2100 mPas at 150*C (DIN 53018, Brookfield DV II, Sp. 21). The glass transition by the abovementioned method was - 10*C. 25 Using a nozzle, the self-adhesive composition was applied over the full area to the backing. Direct coating took place at 50 m/min and at a temperature of 120 0 C. The backing material was coated with 170 g/m 2 30 The plaster material produced in this way shows a comparatively good release of the active substance. _j
Claims (20)
1. Backing material for medical purposes, character ized in that the backing material is a nonwoven 5 overstitched by means of yarns and having an ultimate tensile stress strength of at least 10 N/cm and in that the backing material is coated partially or over its full area on at least one side with a doped adhesive composition. 10
2. Backing material for medical purposes, characterized in that the backing material is a nonwoven which is reinforced by the formation of stitches formed by loops from the fibres of the 15 web, the ultimate tensile stress strength of the backing material being at least 10 N/cm, and in that the backing material is coated partially or over its full area on at least one side with a doped self-adhesive composition. 20
3. Backing material for medical purposes according to Claim 1 or 2, characterized in that the number of stitches on the web, in particular longitudinal stitches, is at least 3/cm, preferably from 5 to 25 50/cm.
4. Backing material for medical purposes according to Claim 4, characterized in that the backing material generates a compression force of from 0.2 N/cm to 30 10 N/cm at an elongation of from 20% to 70%.
5. Backing material for medical purposes according to Claim 1 or 2, characterized in that the backing material has a basis weight of up to 500 g/m 2 , 35 preferably from 10 to 35 -- g/m 2 - 35
6. Backing material for medical purposes according to Claim 1 or 2, characterized in that the backing material is reinforced with one or more monofil, multifil, staple fibre or spun fibre yarns and/or 5 with oriented high-strength fibres, the yarns and/or fibres having in particular a strength of at least 40 cN/tex.
7. Backing material for medical purposes according to 10 Claim 7 [sic], characterized in that the backing material can be torn by hand perpendicular to the orientation of the stitches and/or in the direction of the stitches and/or perpendicular to the orientation of the reinforcement and/or in the 15 direction of the reinforcement.
8. Backing material for medical purposes according to at least one of the preceding claims, characterized in that the adhesive composition comprises the 20 releasable active substance or substances in an amount of from 0.01 to 60% by weight, preferably from 0.1 to 20% by weight.
9. Backing material for medical purposes according to 25 at least one of the preceding claims, characterized in that the adhesive composition is a hot-melt adhesive composition.
10. Backing material for medical purposes according to 30 at least one of the preceding claims, characterized in that the adhesive composition has a dynamic complex glass transition temperature at a frequency of 0.1 rad/s of less than 150C, preferably from 30C to -30 0 C, with very particular preference from -3*C 35 to -250C. - 36
11. Backing material for medical purposes according to at least one of the preceding claims, characterized in that the adhesive composition was foamed. 5
12. Backing material for medical purposes according to at least one of the preceding claims, characterized in that the adhesive composition is applied partially to the backing material, especially by halftone printing, thermal screen printing, thermal 10 flexographic printing or intaglio printing.
13. Backing material for medical purposes according to at least one of the preceding claims, characterized in that the adhesive composition has been sprayed 15 on.
14. Backing material for medical purposes according to at least one of the preceding claims, characterized in that the adhesive composition is applied in the 20 form of polygeometric domes to the backing material.
15. Backing material for medical purposes according to at least one of the preceding claims, characterized 25 in that the adhesive composition is applied to the backing material with a weight per unit area of greater than 15 g/m 2 , preferably between 90 g/m 2 and 500 g/m 2 , with very particular preference between 130 g/m 2 and 500 g/m 2 . 30
16. Backing material for medical purposes according to at least one of the preceding claims, characterized in that the adhesive composition can be sterilized, preferably with y (gamma) radiation. 35
17. Backing material for medical purposes according to - 37 one or more of the preceding claims, characterized in that on the side opposite that coated with the self-adhesive composition, the backing material is finished with a water-repellent layer, impreg 5 nation, release layer and/or coating.
18. Backing material for medical purposes according to one or more of the preceding claims, characterized in that at least one additional layer comprising 10 sheets, foams or nonwovens is applied on the backing material.
19. Backing material for medical purposes according to one or more of the preceding claims, characterized 15 in that the backing material is coated with metallic substances by vapour deposition.
20. Backing material for medical purposes according to one or more of the preceding claims, characterized 20 in that the coated backing material is covered after application of the self-adhesive composition or is provided with a wound pad or with padding.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19804774A DE19804774A1 (en) | 1998-02-06 | 1998-02-06 | Substrates for medical purposes |
DE19804774 | 1998-02-06 | ||
PCT/EP1999/000738 WO1999039756A2 (en) | 1998-02-06 | 1999-02-04 | Supporting material for medicinal purposes |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2521799A true AU2521799A (en) | 1999-08-23 |
AU752378B2 AU752378B2 (en) | 2002-09-19 |
Family
ID=7856862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU25217/99A Ceased AU752378B2 (en) | 1998-02-06 | 1999-02-04 | Supporting material for medicinal purposes |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1053030B1 (en) |
AT (1) | ATE226833T1 (en) |
AU (1) | AU752378B2 (en) |
DE (2) | DE19804774A1 (en) |
ES (1) | ES2185317T3 (en) |
WO (1) | WO1999039756A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19840191A1 (en) * | 1998-09-03 | 2000-03-09 | Lohmann Therapie Syst Lts | Medicinal plaster with three functional layers |
DE19921743A1 (en) * | 1999-05-11 | 2000-11-16 | Beiersdorf Ag | Cohesive carrier material |
DE10020102A1 (en) * | 2000-04-22 | 2001-10-25 | Beiersdorf Ag | Procedure for partial application of high viscosity fluids to base material entails using nozzle with geometry such that at mouth of nozzle's fluid discharge gap a pressure increase takes place |
DE10032537A1 (en) * | 2000-07-05 | 2002-01-31 | Labtec Gmbh | Dermal system containing 2- (3-benzophenyl) propionic acid |
ITTV20020008A1 (en) * | 2002-01-25 | 2003-07-25 | Al Pre Tec S R L Allergy Preve | PROCEDURE FOR OBTAINING A SILK MANUFACTURE INDICATED IN THE TREATMENT OF CERTAIN SKIN AFFECTIONS OF THE HUMAN BODY |
DE10207776A1 (en) * | 2002-02-23 | 2003-09-04 | Tesa Ag | Process for the production of a partially coated plaster |
DE10236319A1 (en) * | 2002-08-08 | 2004-02-19 | Beiersdorf Ag | Active agent containing matrix plaster for the controlled delivery of an active agent to the skin comprises a pharmaceutical active agent containing a water insoluble adhesive matrix comprising a styrene block copolymer |
DE20216598U1 (en) | 2002-10-23 | 2003-03-20 | Dehn, Michael C., 20099 Hamburg | Wart-removing product comprises an air-impermeable covering |
DE10306187B4 (en) * | 2003-02-13 | 2005-08-04 | Steffen Barth | plaster |
DE102004058140B4 (en) * | 2004-11-25 | 2007-09-20 | Tesa Ag | Hydroactive plaster with three-dimensional tangle coating |
US20070179461A1 (en) * | 2006-02-02 | 2007-08-02 | Bristol-Myers Squibb Company | Hot-melt silicone based ostomy and wound care skin attachment adhesives |
DE102011081818A1 (en) * | 2011-08-30 | 2013-02-28 | Beiersdorf Ag | Active skin coatings |
US20210007899A1 (en) * | 2018-04-02 | 2021-01-14 | Marine Biology & Environmental Technologies, Llc | Medical dressings and uses therof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4967740A (en) * | 1986-06-11 | 1990-11-06 | Minnesota Mining And Manufacturing Company | Dispensable tapes |
US5342685A (en) * | 1992-05-18 | 1994-08-30 | Minnesota Mining And Manufacturing Company | Hot-melt-coatable adhesives |
DE4224325C1 (en) * | 1992-07-23 | 1994-02-10 | Sanol Arznei Schwarz Gmbh | Active ingredient plasters for low-melting and / or volatile active ingredients and process for its manufacture |
DE4237252C2 (en) * | 1992-11-04 | 1994-10-13 | Zweckform Buero Prod Gmbh | Flexible, removable, residue-free removable fabric, process for its production and its use |
DE4442092C2 (en) * | 1994-11-25 | 1996-12-05 | Beiersdorf Ag | Backside coated adhesive tape based on sewing fleece and its use |
DE19531291A1 (en) * | 1995-08-25 | 1997-02-27 | Beiersdorf Ag | Substrates for medical purposes |
DE19631422A1 (en) * | 1996-08-06 | 1998-02-12 | Beiersdorf Ag | Carrier materials equipped with self-adhesive |
-
1998
- 1998-02-06 DE DE19804774A patent/DE19804774A1/en not_active Withdrawn
-
1999
- 1999-02-04 DE DE59903247T patent/DE59903247D1/en not_active Expired - Lifetime
- 1999-02-04 EP EP99904855A patent/EP1053030B1/en not_active Expired - Lifetime
- 1999-02-04 ES ES99904855T patent/ES2185317T3/en not_active Expired - Lifetime
- 1999-02-04 WO PCT/EP1999/000738 patent/WO1999039756A2/en active IP Right Grant
- 1999-02-04 AU AU25217/99A patent/AU752378B2/en not_active Ceased
- 1999-02-04 AT AT99904855T patent/ATE226833T1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2185317T3 (en) | 2003-04-16 |
DE59903247D1 (en) | 2002-12-05 |
EP1053030A2 (en) | 2000-11-22 |
ATE226833T1 (en) | 2002-11-15 |
WO1999039756A2 (en) | 1999-08-12 |
AU752378B2 (en) | 2002-09-19 |
EP1053030B1 (en) | 2002-10-30 |
DE19804774A1 (en) | 1999-08-12 |
WO1999039756A3 (en) | 1999-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6555730B1 (en) | Supporting material for medical purposes | |
AU736935B2 (en) | Active substance plasters | |
JP3847088B2 (en) | Percutaneous absorption therapy system comprising a storage pressure sensitive adhesive layer and a unidirectional elastic backing layer | |
AU752378B2 (en) | Supporting material for medicinal purposes | |
US7063859B1 (en) | Barrier film lined backing layer composition and method for topical administration of active agents | |
US6459013B1 (en) | Supporting material for medical purposes | |
US6544910B2 (en) | Backing material for medical purposes | |
KR20060108511A (en) | Adhesive preparation | |
US6656491B1 (en) | Active substance plasters | |
US6488958B1 (en) | Plasters containing active substances | |
WO2006018340A1 (en) | Active agent-containing plaster strip for treating joint diseases | |
AU755609B2 (en) | Device for releasing substances | |
AU731199B2 (en) | Plasters for percutaneous absorption | |
AU762507B2 (en) | Support material with a cohesive adhesive substance | |
JP2001057991A (en) | Air permeable pasting agent and its production | |
JPH07144017A (en) | Production of air permeable tacky adhesive tape |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SREP | Specification republished | ||
FGA | Letters patent sealed or granted (standard patent) |